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Abstract
Objectives
To systematically review cost of illness studies for schizophrenia (SC), epilepsy (EP) and
type 2 diabetes mellitus (T2DM) and explore the transferability of direct medical cost across
countries.
Methods
A comprehensive literature search was performed to yield studies that estimated direct
medical costs. A generalized linear model (GLM) with gamma distribution and log link was
utilized to explore the variation in costs that accounted by the included factors. Both
parametric (Random-effects model) and non-parametric (Boot-strapping) meta-analyses
were performed to pool the converted raw cost data (expressed as percentage of GDP/cap-
ita of the country where the study was conducted).
Results
In total, 93 articles were included (40 studies were for T2DM, 34 studies for EP and 19 stud-
ies for SC). Significant variances were detected inter- and intra-disease classes for the
direct medical costs. Multivariate analysis identified that GDP/capita (p<0.05) was a signifi-
cant factor contributing to the large variance in the cost results. Bootstrapping meta-analysis
generated more conservative estimations with slightly wider 95% confidence intervals (CI)
than the parametric meta-analysis, yielding a mean (95%CI) of 16.43% (11.32, 21.54) for
T2DM, 36.17% (22.34, 50.00) for SC and 10.49% (7.86, 13.41) for EP.
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Conclusions
Converting the raw cost data into percentage of GDP/capita of individual country was dem-
onstrated to be a feasible approach to transfer the direct medical cost across countries. The
approach from our study to obtain an estimated direct cost value along with the size of spe-
cific disease population from each jurisdiction could be used for a quick check on the eco-
nomic burden of particular disease for countries without such data.
Introduction
With greater emphasis on rational distribution of healthcare resources, the availability of
economic evaluation has increased dramatically in recent decades. However, there is still a
paucity of local economic evaluation to assist many jurisdictions that are attempting to
make reimbursement decision. In interpreting these results from other jurisdictions, deci-
sion-makers need to form a view on whether the results are transferable into their own
settings. In health economics, transferability refers to adopt the results from foreign studies
to one particular country with/without certain adaptations, while does not need a new
national study for that medical technology. However, the sometimes huge difference in
health care systems, such as the variation in clinical practice patterns (e.g. the difference in
hospitalization rate), in relative prices, and the availability of the alternative treatments, hin-
ders such attempt [1–3].
To appreciate the difficulties encountered by the decision makers in adopting economic
evaluation from other jurisdiction, we need to examine what type of information needs to be
deciphered. When considering the decision about cost-effectiveness of any new health treat-
ment or technology, the obvious answer is whether the incremental cost-effectiveness ratio
(ICER) is applicable locally. An ICER comprises of a cost component and an effect component.
The decision makers will need to evaluate whether these two components individually and col-
lectively from a published study can be applied in their own jurisdictions. Management of vari-
ous diseases or disorders is fairly standardized internationally and thus the effect component
may pose fewer problems. Often times, it is the cost component that is creating more concern
when trying to transfer across jurisdictions.
From the societal perspective, the economic cost of an illness has three important compo-
nents: direct costs, indirect costs and intangible costs. Due to various unresolved technical and
theoretical issues, in most economic evaluation, intangible cost is usually not reported or
included. For the two remaining components: indirect cost has previously been demonstrated
to be transferrable when local data were unavailable by our research group [4]; while the issue
of whether the direct cost component is transferrable still remains unresolved. In order to
answer this question, we would need to gather information from Cost-of-illness studies per-
formed internationally.
Cost of illness (COI) is one form of economic studies and it is often used to estimate the
economic burden of a particular disease. Such knowledge can help policy makers to set pri-
ority in health care manpower planning, resource allocation and prevention policy [5–8].
Most importantly, COI studies are able to show whether new treatments could be valuable in
reducing the burden of a specific disease. It can also provide important information for cost-
effectiveness and cost-benefit analysis by providing the cost estimation in these analyses. As
a tool, COI study is a better capture of cost information for treating a disease compared to
cost-effectiveness or cost-utility analysis. In practice, cost-effectiveness or cost-utility
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analysis only concerns the direct medical cost estimates for different health states or events
that are tracked over time in a model, whereas COI studies typically estimate all costs related
to that disease over a year (prevalence-based) or even over a life-time (incidence-based). It
would provide more information for decision-makers in terms of costs. Ideally, if COI could
be conducted for various diseases and disorders locally, the information could be utilized by
the decision makers immediately. Unfortunately, this is not the case and for most diseases,
local COI study is not available, especially for a lot of developing countries.
Aside from the substantial resources required to carry out COI study, even if it is feasible for
each jurisdiction to conduct a COI study to gauge the economic burden of a disease, there will
be substantial time delay affecting funding recommendations for new programs [2].A reference
value for a quick check on the cost of a particular disease would really be helpful for decision-
makers needing to make a decision within a very short time frame. To date, the vast majority of
studies performed were to explore the transferability of cost-effectiveness studies. A literature
review indicated that the factor most frequently cited as generating variability in economic
results between locations was the unit costs associated with particular resources, e.g. the abso-
lute or relative prices of resources [9]. Accordingly, several statistical methods have been pro-
posed to tackle the problem of distinguishing location-specific costs. Studies have been
performed using regression model to look at variability in the cost among six European coun-
tries based on data from a randomized trial. Using country-specific unit costs, individual
patients’ costs within each country were summated. However, it was concluded that it was diffi-
cult to pool the cost data from the six countries due to significant differences among them and
the authors also emphasized the importance of separating resource use from cost rather than
simply reporting and analysing total costs[10]. A similar method using an adjusted resource
quantity to a “typical treatment” pattern of the target country while substituting the unit prices
of the target country was also proposed [11]. Other researchers suggested running regression
analysis on cost components where variation between locations is evident, to assess the degree
to which variation can be explained by various factors[12]. Nevertheless, none of the aforemen-
tioned methods can provide a reference value for decision-maker with limited or no informa-
tion. Approaching from another angle, confirmation of the transferability of COI study across
jurisdiction would contribute significantly to resolving the issue of transferability of cost-effec-
tiveness results.
However, COI studies varied substantially in terms of perspective, cost component, source
of data, calculating methods, the time frame of measurement and therefore the final result [13].
Due to these heterogeneities, studies have rarely been conducted to explore transferability of
COI studies from country to country. So far, only one recent study has been carried out to
investigate the transferability of COI study (indirect cost due to chronic diseases)[4]. In this
study, after transforming the monetary value into percentage of GDP per capita, the large vari-
ation in indirect cost became much narrower across the studies, thus providing a meaningful
reference range to estimate indirect cost. While this may solve the issue of transferability of
indirect cost, direct cost especially the direct medical cost is still an irreplaceable cost compo-
nent and the primary concern from the healthcare provider’s/third party perspective. There-
fore, transferring direct medical costs across countries (or at least providing some meaningful
interpretation) could considerably aid the healthcare decision-making, particularly for coun-
tries with limited resource and research output. Hence, in our current study, three chronic dis-
eases were selected—type 2 diabetes mellitus, epilepsy and schizophrenia to review the direct
medical cost via meta-analysis with the aim of identifying the primary determinants for this
cost component, and the transferability across countries.
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Methods
Search strategies and selection criterion
Electronic databases including Medline, Embase, Cochrane Library and EconLit were searched
from inception to 15th April, 2013. The following terms were used to locate the relevant litera-
tures: cost of illness, cost, burden of illness, cost analysis; and then followed by a disease filter
with ‘type 2 diabetes mellitus’ (T2DM), ‘epilepsy’ (EP), or ‘schizophrenia’ (SC) as key words
separately. For the different searches, phrases were conjoint by Boolean operators “AND” and
“OR” (The electronic search strategy is provided Supplementary document). In addition, man-
ual search was also performed of references from identified literatures. Since the present study
intended to adopt the healthcare system perspective, direct non-medical cost was beyond the
scope of our research.
Inclusion criteria (studies should satisfy all the following criteria):
1. Patients were diagnosed with T2DM, EP or SC.
2. It was original research.
3. Direct medical cost should at least encompass three of the following cost components: hos-
pitalisation, outpatient, medication, examination/laboratory test/procedure.
4. Direct medical cost per patient annually was reported or could be calculated in monetary
term.
5. Estimation was based on incidence or prevalence of the disease of interest.
6. Studies utilized bottom-up, top-down, econometric or modelling method to calculate the
direct medical cost.
At first, titles and abstracts of all the yielded articles were used to screen out irrelevant litera-
tures. Then, full-text of the remaining ones were reviewed and checked on the eligibility for
inclusion.
Literature synthesis
A standardized collection form was used to extract data from eligible studies. Extracted data
included year of publication/conduction, country/region of study, data source, calculation
method, incidence or prevalence-based, retrospective or prospective, number of patients,
demographic characteristics of patients, monetary value of direct medical cost and each com-
ponent’s cost. Specific year of currency exchange rate was used to convert the reported cost
into US dollars, and adjusted to 2011 value based on US consumer price index (CPI). If the
year of study conduction was not explicitly stated, the publishing year was adopted. The Gross
Domestic Product (GDP) per capita in 2011 for the included countries was obtained from the
World Bank [14]. The direct medical cost was expressed as percentage of the particular coun-
try’s GDP/capita in 2011.
Data analysis
Multivariate analysis. In order to identify the factors that contributed to the large varia-
tion in the direct medical cost, generalized linear model with gamma distribution and log link
was employed to examine the effects of categorical and continuous variables on the raw direct
medical cost given the skewness of the cost data. In this process, direct medical cost was
selected as the dependent variable and the methodological (e.g. data source [published litera-
ture, database, survey], calculation method [bottom-up, top-down, modelling], were dummy
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coded where applicable) and socio-demographical variables (GDP/capita) were treated as fixed
factors in this model.
Meta-analysis. For the meta-analysis, direct medical cost expressed as percentage of GDP
per capita was input as the individual cost estimate. Both parametric (Random effects) [15]
and Non-parametric (Bootstrapping) methods [16] were adopted to compute the mean and
95% confidence intervals (CI) of the weighted cost estimate [4]. Since random-effects model
accounts for the random effects variance, which represents the variability across the population
effects, the biggest difference between fixed-effects and random-effects models is the signifi-
cance levels (effects that were significant under a fixed-effects model may no longer be signifi-
cant) and confidence intervals (confidence intervals will get bigger). Furthermore, if sample
size is highly related to cost estimate, then the mean cost estimate will differ between the two
models. So the random-effects model will generate more conservative result comparing to
fixed-effects model and the fixed-effects model was not adopted in our analysis. For the boot-
strapping analysis, a random number of studies with replacement were chosen and then a
weighted mean cost estimate was calculated in the bootstrapping method. This process was
repeated for another 1999 times, the output values were rank-ordered sequentially, and the
lowest and highest 2.5% values chosen as the bootstrap confidence limits. As majority of the
included studies did not present the variance of annual cost probably due to highly skewed
data, the cost estimate was weighted by the sample size of each study instead of variance in
parametric meta-analysis [15]. In order to further compare the raw cost and converted percent-
age of GDP/Capita, the within- and between-country variations were calculated using country
of origin as the clustering factor before and after the conversion for the total cost. Moreover,
the intraclass correlation coefficient (ICC or ρ) was estimated using the between-country and
within-country variations calculated above.
For missing values on sample size in the studies, they were replaced by the average of
remaining studies for that particular variable within a disease subgroup for the meta-analysis.
In addition, in order to avoid putting unbalanced weight on study with extreme sample size,
sample size for studies with greater than 10,000 subjects were replaced with 10,000. Therefore,
sample sizes of 16, 7 and 4 studies from T2DM, SC and EP disease groups were truncated
through this approach, respectively. Data were analyzed using SPSS 20.0 (SPSS Inc. Chicago,
IL, USA) and Microsoft Excel. A detailed protocol is presented in supplementary document.
Results
Identify the relevant studies
The initial electronic database search yielded 2987 papers, but 2839 were excluded based on
screening of titles and abstracts. Then the remaining 148 articles were retrieved for full-text
review to further examine the eligibility. However, 55 studies were not included as they only
addressed one specific aspect of the disease or per capita direct cost was not provided (or could
not be calculated). After this culling process, 93 studies finally met the inclusion criteria for the
study. There were 40 studies for T2DM [17–56], 34 studies for EP,[57–90] and 19 studies for
SC [91–109]. The detailed culling process was shown in Fig 1.
Description of the included studies
The characteristics of each included study and a summary of all the included studies based on
the disease group were presented in Table 1 and S1 Table. Generally, all studies addressed cost
components for outpatient care, medications, examination and/or hospitalization, though not
all presented those components along with the total cost.
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Several studies presented different estimations for various patient subgroups, thus each was
treated as an independent study and the results were shown separately[27, 29, 30, 39, 45, 46,
63, 67, 78, 108].
For T2DM, there were 48 studies (including six studies that provided cost values for differ-
ent subgroups, with two of these studies estimated the costs for three subgroups) (15, 17, 18,
Fig 1. Selection process of the eligible studies.
doi:10.1371/journal.pone.0147169.g001
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27, 33, 34) performed in 23 countries from 1992 to 2012 (S1 Table). All the studies estimated
direct medical cost based on prevalence. Among these, 23 (47.9%) studies utilized the survey
approach and published literatures/expert opinions to generate the data. 19 studies (39.6%)
used the top-down method by accessing the national statistics or regional databases to calculate
the cost. Only one study (2.3%) adopted the prospective perspective to collect data. In terms of
cost components, more than 65% of the studies reported individual cost for hospitalization,
outpatient care and medications, whereas only 9 (18.8%) studies presented the costs for exami-
nations explicitly. As a result, the estimated direct medical cost ranged from $104 (India) to $
20568 (USA), showing a huge range from developing to developed countries.
In EP group, 37 studies (three studies estimated the costs using different methods) (51, 55,
66) were conducted in 15 countries between 1990 and 2011. A majority of studies (20 studies,
54.1%) using survey data as their data sources. 30 and 7 studies computed the cost based on
prevalence and incidence respectively. Bottom-up (23 studies) and retrospective (30 studies)
data collection approaches were still being more frequently used than top-down and prospec-
tive methods. Availability of cost for hospitalization, outpatient care, medication, examination
were the greatest for this disease group, with more than 80% of the studies reporting each of
the cost components. Finally, the average direct medical cost varied from $2 (Burundi) to
$13787 (USA) per annum.
For SC group, 21 studies (the Spanish study was divided into three studies according to dif-
ferent prevalence estimations (96)) were carried out in 16 countries from 1990–2008. Again,
greater number of studies used survey data and all the studies estimated direct medical cost by
the prevalence-based approach. Retrospective data collection method was used in 5 studies
(23.8%).More than 60% of studies explicitly reported the cost for inpatient, outpatient care and
medication costs, but none presented the costs for examination. The reported annual direct
medical costs for epilepsy patient amounted from $101 (Nigeria) to $33627 (England).
Contributor to the variation in direct medical cost
With direct medical cost as dependent variable, categorized, year of publication, GDP/capita,
data source, calculation method, and time perspective were entered into the model as fixed fac-
tors. As a result, GDP/capita contributed considerably to all three models for T2DM, EP, and
SC (Tables 2–4). Due to limited number of studies in each model, other variables that signifi-
cantly contributed to models were inconsistent across three diseases, which disabled us to draw
any reliable conclusion.
Table 1. Characteristics of literature synthesis.
Disease Time
range
Countries Survey
design
(%)
Prevalence-
based
study (%)
Bottom-
up
design
(%)
Prospective
study (%)
Inpatient
cost
reported
(%)
Outpatient
cost
reported
(%)
Medication
cost
reported
(%)
Tests
cost
reported
(%)
Characteristics
of subjects (%)
Range
of direct
medical
costs
(USD)
DM 1992–
2012
23 23
(47.9)
48(100) 23
(47.9)
1 (2.1) 32 (66.7) 33 (68.7) 35 (72.9) 9 (18.7) 25 (52.1) 164–
20568
EP 1990–
2011
15 20
(54.1)
30 (81.1) 23
(62.2)
7 (18.9) 34 (91.9) 33 (89.2) 35 (94.6) 32(86.5) 23 (62.2) 2–13787
SC 1990–
2008
16 13
(61.9)
20 (95.2) 14
(66.7)
5 (23.8) 14 (66.7) 13 (61.9) 13 (61.9) 0 (0) 10 (52.4) 101–
33627
Studies with multiple estimations were deemed as different studies.
DM: diabetes mellitus; SC: schizophrenia; EP: epilepsy.
doi:10.1371/journal.pone.0147169.t001
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Meta-analysis
In general, direct cost expressed as a percentage of GDP/capita showed substantially narrower
95% CI than the cost expressed in US dollar values. The meta-analysis results based on
parametric and non-parametric methods did not differ substantially from each other for all
Table 2. Results from generalized linear model analysis (Type 2 Diabetes Mellitus).
Tests of Model Effects
Source Type III
Wald Chi-Square df Sig.
(Intercept) 870.654 1 <0.0001
Publication period 3.459 2 0.177
Methods of cost computation 1.983 2 0.371
Data source 2.380 2 0.304
Longitudinal study 13.217 1 <0.0001
GDP/Capita 508.481 22 <0.0001
Number of study: 48.
doi:10.1371/journal.pone.0147169.t002
Table 3. Results from generalized linear model analysis (Epilepsy).
Tests of Model Effects
Source Type III
Wald Chi-Square df Sig.
(Intercept) 1006.374 1 <0.0001
Publication period 7.815 2 0.020
Methods of cost computation 10.541 2 0.005
Data source 32.857 5 <0.0001
Longitudinal study 0.974 1 0.324
GDP/Capita 658.594 15 <0.0001
Number of study: 37.
doi:10.1371/journal.pone.0147169.t003
Table 4. Results from generalized linear model analysis (Schizophrenia).
Tests of Model Effects
Source Type III
Wald Chi-Square df Sig.
(Intercept) 28104.449 1 <0.0001
Publication period 26.147 2 <0.0001
Methods of cost computation 216.785 1 <0.0001
Data source 211.113 1 <0.0001
Longitudinal study 125.762 1 <0.0001
GDP/Capita 13632.364 10 <0.0001
Number of study: 21.
doi:10.1371/journal.pone.0147169.t004
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disease groups. Particularly, means and 95% CIs of the synthesized results derived from ran-
dom-effects model and bootstrapping estimation were similar. The converted direct medical
costs for DM, SC and EP were ranged between 10% and 23%, 19% and 53%, 7% and 13% of
GDP/capita according to different estimation methods respectively, on contrast, the interquar-
tile ranges of raw costs were between $906 and $5879, $3456 and $23310, $1586 and $4848,
separately. Still, SC incurred higher direct medical cost than the other two diseases (Table 5).
The between-country variation demonstrated that the GDP/Capita adjusted total cost had
substantially lower between country heterogeneities than the raw total cost (2.45 vs. 0.28)
(Table 6).
Discussion
Our study systematically reviewed cost of illness studies addressing the direct medical cost for
type 2 diabetes mellitus, epilepsy and schizophrenia and explored the determinants for the vari-
ation in this cost component. Unsurprisingly, the direct medical costs varied substantially
across different countries. The discrepancy existed among the developed countries (and some-
times even studies for the same country), would render meaningless any attempt for the meta-
analysis of COI studies if the raw data were used. Furthermore, it was reported that resource
use is considered of low transferability in a review of pharmacoeconomic guidelines in regard
to transferability of economic data, obviously, it is beyond argument. However, converting the
raw cost into a new currency (percentage of GDP/Capita) is different from those discussed in
the review, which may aid to resolve this problem[110]. After converting the raw value of direct
medical cost into percentage of local GDP/capita, the variation of the direct medical cost
reduced markedly, which was supported by the reduced between-country variation. The ICC
Table 5. Raw cost andmeta-analysis of direct medical costs.†
Raw cost Random effect Bootstrapping
Median (IGR) Mean (95% CI) Mean (95% CI)
Diabetes Mellitus $3186.50 16.4666‡ 16.4283
(906, 5878.75) (10.2033, 22.7299) (11.3242, 21.5425)
Schizophrenia $8332.00 36.2242& 36.1686
(3455.50, 23310.00) (19.1496, 53.2988) (22.3380, 49.9991)
Epilepsy $2660.0 10.3798§ 10.4916
(1585.50, 4847.50) (7.4273, 13.3322) (7.8604, 13.41229)
IGR: interquartile range.
† direct medical costs were expressed as percentage accounted for the GDP/Capita.
‡Q = 30.77, I2 = 0
&Q = 13.38, I2 = 0
§ Q = 28.49, I2 = 0.
doi:10.1371/journal.pone.0147169.t005
Table 6. Comparison of between and within country variation in total cost.
Between-country variation Within-country variation ICC (ρ)
Raw cost data 2.454 0.394 0.86
GDP/Capita adjusted cost data 0.279 0.428 0.39
ICC: intracluster correlation coefﬁcient.
doi:10.1371/journal.pone.0147169.t006
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of the raw cost data was greater than the converted cost as the GDP/capita is a differentiating
factor rather than a correlation factor. The proposed method is able to reduce the between-
country variance while does not alter the within country variance. Ideally, each study should be
weighted by the inverse variance from that study in the meta-analysis. However, a large num-
ber of the studies did not report the 95% confidence interval or the standard deviance, which
makes using such weighting method unrealistic. As an alternative, the sample size was adopted
to approximately weight each study in our meta-analysis. In addition, non-parametric meta-
analysis method (boot-strapping meta-analysis) was performed to further test the robustness
of our results.
Via these two approaches, the mean and 95% CI of the direct medical cost of each included
disease was estimated as the percentage of local GDP/capita, and this substantially reduced the
ranges of variations in the direct medical costs across countries. Hence, our study provided a
new potential approach to transfer the direct medical cost across countries. The synthesis of
direct medical cost of commonly occurring chronic diseases along with the patient population
size of that particular disease could be employed to provide a quick check of the burden of the
disease when such information is not readily available. For example, with an extremely limited
healthcare budget, the policy-makers in China need to decide whether to reimburse an antiepi-
leptic drug or an anti-schizophrenia drug provided that these two drugs have very similar
Incremental Cost-effectiveness Ratio values. This would be difficult if the direct treatment
costs for the two diseases were unavailable. In this case, using the approach from our present
study of utilizing information from other jurisdictions together with the sizes of these two
patient populations can help policy-makers to set the priority and make the reimbursement
choice. Additionally, this information can also provide an estimate of the quantum of changes
in direct costs of any claimed benefits from a new drug or intervention at the population level.
There are several rationales for using the GDP/capita to adjust the direct medical cost.
Firstly, as demonstrated in the multivariable analysis, GDP/capita was positively associated
with direct medical cost. It is also well acknowledged that the difference in health care systems
is an independent factor causing the variability in the direct medical cost (as countries may
vary in terms of the types and magnitude of health care resources, programs, or services that
are available). Furthermore, the development of health care system is always determined by the
economic status of the individual country. For instance, the highest cost of each disease was
always generated by the developed country from our study (USA and England), as absolute
and relative prices in healthcare, practice variation and technology availability all have direct
impact on either direct medical cost or cost of care[111]. Since GDP/capita is a widely accepted
index to measure the economic performance of a country, adjusting the direct medical cost by
GDP/capita could account for the variability caused by health care system to a large extent.
The results from our present study supported the feasibility of such conversion. Certainly,
other factors associated with cost variability such as characteristics of patients (demographics,
types of insurance coverage), disease (epidemiology, disease mortality), provider (clinical prac-
tice, guidelines) and methodologies (costing method, study perspective) also contribute to the
difference in the medical cost estimation.[2] Nonetheless, the possible impact of these factors
may be accounted for by the 95% CI of the values. Therefore, based on the assumption of the
economic status of each country and the health care system are the major contributors to the
large variation in direct medical costs across jurisdictions, it is feasible to synthesize the direct
medical cost expressed as the percentage of GDP/capita to establish the bounds of each chronic
disease to provide informative data to country/jurisdiction without such information. The esti-
mates (with its 95% CI) would also serve as a comparator of assessing service efficiency for
country/jurisdiction with such data.
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A previous study from our research group utilized the same approach to transform the indi-
rect cost including the mortality and caregiver’s costs into percentage of GDP/capita, and dem-
onstrated the feasibility of the approach in allowing transferability of indirect cost data across
jurisdictions [4]. Our current study broadened the potential usefulness of such approach to
direct medical cost. The transferring of both direct and indirect medical costs across jurisdic-
tions can provide a more comprehensive view on economic burden of a particular disease
when making any health resource allocation decision in lieu of local information.
Practically, the usefulness of our study would largely be for developing countries where eco-
nomic evaluation study is seldom conducted. With the increasing constraints in health budget
and the ever-escalating demands internationally, it is necessary to adopt economic evaluation
in supporting the health care decision-making. The missing information on the economic bur-
den of chronic disease would definitely hamper the rational distribution of health resource,
particularly in developing countries where resource is more limited. Therefore, the approach
from our study could offer a mean of obtaining this reference information to assist in decision
making. Even in countries with these data, the mean value from pooled studies could be uti-
lized for benchmarking comparisons.
Nevertheless, the predictive capability of the constructed mean and range in predicting
direct medical cost of DM, EP and SC in a country not included in our study needs to be vali-
dated by more studies. For instance, it would be desirable to use our method to predict the
direct medical cost in a jurisdiction prior to conducting a study to directly estimate the direct
medical cost. Researchers should apply caution to directly utilize the 95% CI from the boot-
strap meta-analysis to construct a 95% CI for a target country not yet studies in the presented
meta-analysis as the CI obtained by bootstrap method is a confidence interval for the mean
rather than that for an individual country.
Inherently, several limitations are worth mentioning. First of all, due to the difference in the
economic status affecting resource availability, patients with those chronic diseases in develop-
ing countries may not be managed optimally according to the international guidance. How-
ever, expressing direct medical cost as percentage of GDP/capita might minimize such impact
to a certain extent. Second, the heterogeneities in the methodology of each study also intro-
duced another uncertainty. To compensate, we tried to integrate the methodological variables
into the multivariate analysis model. From the result, data source, year of study conduction,
time perspective (retrospective or prospective), and disease definition (incidence or preva-
lence-based) were not significant contributors to the model. Third, only three chronic diseases
were investigated in the present study, further study utilizing the same method on other dis-
eases would enhance the generalizability and validity of our approach. It is planned that with
the emerging of more COI studies reporting on the included diseases, an external validation of
the proposed method could be performed via reconverting the percentage of GDP/capita to the
monetary form (percentage of GDP/Capita× GDP/Capita from particular country of interest),
to see if the direct medical cost from a new study could fall within the range constructed in the
presented study.
Conclusions
The direct medical cost for schizophrenia, type 2 diabetes mellitus and epilepsy varied substan-
tially across different countries and even for the same country. However, when converted the
raw cost data into percentages of GDP/capital of each country, the variance in the cost became
much narrower. Pooling the converted raw cost data can be of help to construct a reference
range for other countries without such data. The mean percentage of GDP/capita estimate can
be converted back to the monetary value of the jurisdiction of the decision maker. When
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combined with the size of patient population in a jurisdiction, it can provide a quick check on
the economic burden of a particular disease.
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